Photo: Joe Carrotta/NYU Langone Health via AP. In this September 2021 photo provided by NYU Langone Health, a surgical team at the hospital in New York examines a pig kidney attached to the body of a deceased recipient for any signs of rejection. From left are Drs. Zoe A. Stewart-Lewis, Robert A. Montgomery, Bonnie E. Lonze and Jeffrey Stern. The test was a step in the decades-long quest to one day use animal organs for life-saving transplants.

Scientists temporarily attached a pig’s kidney to a human body and watched it begin to work, a small step in the decades-long quest to one day use animal organs for life-saving transplants.

Pigs have been the most recent research focus to address the organ shortage, but among the hurdles: A sugar in pig cells, foreign to the human body, causes immediate organ rejection. The kidney for this experiment came from a gene-edited animal, engineered to eliminate that sugar and avoid an immune system attack.

Image: Photo: Joe Carrotta/NYU Langone Health via AP. In this September 2021 photo provided by NYU Langone Health, a surgical team at the hospital in New York examines a pig kidney attached to the body of a deceased recipient for any signs of rejection. From left are Drs. Zoe A. Stewart-Lewis, Robert A. Montgomery, Bonnie E. Lonze and Jeffrey Stern. The test was a step in the decades-long quest to one day use animal organs for life-saving transplants.

phlow logo

Phlow is strategically working with the U.S. government to ensure preparedness for future national health crises  

October 20, 2021 09:00 AM Eastern Daylight Time

RICHMOND, Va.--(BUSINESS WIRE)--Phlow Corp., a U.S.-based essential medicines impact company, today announced that it has been approved for inclusion in the Biomedical Advanced Research and Development Authority (BARDA) contract development and manufacturing organization (CDMO) network. The network is part of a comprehensive effort by the U.S. government to provide a domestically integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools to address public health emergencies.  

NewImage

935 Prose is a 10-story trophy-class, state-of-the-art research/lab building that marries iconic design, and superior lab functionality. It is positioned to recruit and retain the best-and-brightest scientific talent and will set a new standard for life science facilities.

Best Articles Banner

Each year BioProcess International publishes over 150 articles focusing on the latest science, technologies, and techniques supporting biopharmaceutical research, development, and manufacturing. As publishers, we work closely with industry authors and our editorial advisory board members to select, edit, and review every article before publication to ensure that it meets the high standard you have come to expect from BPI.

 

Usa flag

The United States is on edge in ways the nation has rarely experienced throughout its young history. The country’s global leadership is being challenged in a rapidly changing and increasingly competitive world. Meanwhile, the nation’s sustained complacency in dealing with long-festering domestic needs has weakened our institutions from within and placed in grave danger our leadership in the critical fields of science and technology—on which so much of our economy and security is based. America is at a tipping point, in short, and Americans are justifiably unsettled.

 

Mr. Kim and Rich Bendis

Mr. Hakdo Kim, President, Korea SMEs & Startups Agency KOSME), joins Rich Bendis from the BHI Offices to discuss their biotech mission, their relationship with Maryland, and opportunities to expand in the United States

Listen now on Apple https://apple.co/2XGxg7i, Google https://bit.ly/3bbuDxz, Spotify https://spoti.fi/2XI5h7n, and TuneIn https://bit.ly/2XGwYNJ.

DoC Logo rgb 1024x786

October 20, 2021    |   By This email address is being protected from spambots. You need JavaScript enabled to view it.

University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that UMSOM has been awarded $1.25 million in matching funds from the Maryland E-Nnovation Initiative Fund (MEIF), administered by the Maryland Department of Commerce. The funds, totaling $2.5 million when combined with private philanthropy, will enable the establishment of a new Center for Pathogen Research. They will also enable UMSOM to support research professorships in the Department of Microbiology and Immunology and the Department of Neurology.

The Alicia and Yaya Foundation made a $750,000 philanthropic commitment to establish the Alicia and Yaya Foundation Professorship in Pathogen Research in the Department of Microbiology and Immunology. Matching state funds bring the total to $1.5 million, which will establish an endowed professorship for Matthew Frieman, PhD, associate professor of Microbiology and Immunology at UMSOM. He will also serve as the director of a new Center for Pathogen Research.

Dane

Danae expands its 3-D Print manufacturing capacity, adds access to unique 3D printing technologies from Materic

October 21, 2021, Baltimore, MD – Danae, Inc., a Baltimore-based 3-D Printing design and manufacturing company, today announced it has partnered with Materic, LLC and received investment from Conscious Venture Partners through their Conscious Venture Fund II.

Located at Baltimore’s 1100 Wicomico, Danae has used this investment to install eight new printers to meet its rapidly growing customer demand. The new machines extend Danae’s capabilities allowing them to manufacture parts using Selective Laser Sintering (SLS) or Stereolithography (SLA) technologies. SLS uses a laser to transform powder into a 3D model whereas SLA uses a laser to cure liquid resin into hardened plastic.

D&D Pharmatech Logo

GYEONGGI-DO, Korea & GAITHERSBURG, Md., October 19, 2021--(BUSINESS WIRE)--D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and parent company of U.S.-based Neuraly Inc., Precision Molecular, Inc., Theraly Fibrosis Inc., P4Microbiome and Valted Seq, today announced that it has completed a $51 million Series C round of financing led by Praxis Capital Partners, a private equity firm that focuses on growth acquisitions and investments in Asia; other investors included DS Asset Management, Kudos Ventures and Korea Investment & Securities. The new round of financing builds upon the $137.1 million the company secured in Series B financing in August 2019. The company is planning an initial public offering in Korea in 2022.

 

Aubry Watkins

ROCKVILLE, MARYLAND, Oct 18, 2020 The Board of Directors of BioHealth Innovation, Inc. (BHI) unanimously approved the appointment of Aubrey Watkins III, Ph.D., M.S. as a new board member. Aubrey Watkins III is a Senior Director, Corporate Development, Scientific Affairs, with Emergent BioSolutions Inc. in Gaithersburg, Maryland; where he leads due diligence and technical evaluations to facilitate mergers and acquisitions that supports the company’s growth strategy. BHI would also like to congratulate Board of Directors members Jarrod Borkat as he takes a new role at CareDx as Vice President Corporate Development, and Bob Silverman in his new role as Chief Business Officer with Rejuveron Life Sciences.

 “I am delighted to welcome Aubrey to our Board of Directors,” said Richard Bendis, BHI President, and CEO. “BioHealth Innovation and Emergent BioSolutions have had a long and productive relationship. We look forward to having Aubrey as a part of this Board to share his experience and perspective.”

BioTalk Divya, Seth and Rich

Listen now via Apple https://apple.co/3BSIFjn, Google https://bit.ly/3j7YyLt, Spotify https://spoti.fi/2Z474Ec, and TuneIn https://bit.ly/3DUweUz.

Divya Chadha Manek was appointed as the NIHR CRN’s Head of Commercial Business Development in 2015 then in 2020, Divya was seconded to the UK Vaccines Taskforce (VTF) which was set up in response to the COVID-19 pandemic to lead the UK’s search for a safe and effective vaccine. Divya was responsible for supporting global pharmaceutical companies to rapidly generate the evidence required for marketing authorisation of COVID-19 vaccines. Divya also played a pivotal role in conceptualising and developing the NHS Vaccine Research Registry.

BHI Logo

BioHealth Innovation (BHI) is an innovation intermediary that facilitates the commercialization of emerging technologies in the BioHealth Capital Region (Maryland, DC and Virginia).

BHI is seeking a Life Sciences Business Strategist to join its team in Rockville, Maryland. This position provides the opportunity to leverage scientific knowledge to evaluate the commercial potential of emerging technologies and provide recommendations on go-to-market strategies.

This is a customer facing role with a focus on supporting clients in the development of commercial analyses and federal grant proposals.

Click here for more details.

Operation room in clinic with medical staff during 2021 08 26 15 46 09 utc

Medical devices are ubiquitous in US healthcare— everything from the delivery room’s sterile gloves and umbilical cord clamps to the breathtakingly sophisticated neurosurgical operating room’s stereotactic navigation systems. More than ever medical devices are a fusion of hardware, software, and even synthetic living material. These are the physical tools through which new life science discoveries improve our lives.